Frontgrade Qualifies Industry’s First Class L GaN DC-DC Converter and EMI Filter
Frontgrade Technologies, a leading provider of mission critical electronics for aerospace and defense, has become the first company to successfully qualify to Class L standards its Gallium Nitride (GaN)-based DC-DC converter and complementary electromagnetic interference (EMI) filter. Under the Defense Logistics Agency’s MIL-PRF-38534 specification, Class L qualification verifies these devices’ ability to meet the most stringent performance requirements of space missions from Low Earth Orbit (LEO) through Geostationary Earth Orbit (GEO).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250217986495/en/
Frontgrade Technologies has become the first company to successfully qualify to Class L standards its GaN-based DC-DC converter and complementary EMI filter. (Photo: Business Wire)
Frontgrade’s new isolated, single-stage converters leverage advanced GaN FET technology to provide spacecraft designers with the industry’s most efficient power conversion modules available today, offering 93% efficiency. With faster switching and improved performance, the company’s GaN DC-DC converter responds rapidly to dynamic power demands and provides multiple voltage outputs for maximum flexibility. This device is designed to convert power seamlessly from the bus to the point of load, ensuring optimal performance for current and future space applications.
“Launching an efficient power solution that has met rigorous Class L qualifications confirms that our GaN converter can reliably address the critical power management needs of next-generation satellites,” said Lorne Graves, Chief Technology Officer at Frontgrade Technologies. “With Frontgrade’s flight-ready modules and evaluation test boards, our customers can accelerate their development cycles to achieve on-time mission success.”
Flight and engineering modules and evaluation test boards are now available, providing the essential tools for development, testing, and deployment in mission-critical spacecraft systems.
About Frontgrade
Frontgrade Technologies is the leading provider of high-reliability, radiation-hardened solutions for defense, intelligence, commercial, and civil applications. The Company offers a complementary and integrated suite of mission critical electronics. Key products include rad-hard components, mission processing subsystems, high power amplifiers, custom ASICs, motion control systems, waveguides, antennas, and power management solutions. For more information, visit www.frontgrade.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250217986495/en/
Contacts
Media Contact
Liz Ryan Sax
719-487-4259
press@frontgrade.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Presidio Investors Welcomes Wynee Sade as Newest Operating Partner28.3.2025 17:32:00 EET | Press release
Presidio Investors is pleased to announce the addition of Wynee Sade as its newest Operating Partner. With over 25 years of global sales and marketing experience, Wynee has held senior leadership roles across a range of industries, including Chief Marketing Officer at Forager Project and leadership positions at Qooco, AppSymth, and Shopkick. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327178560/en/ Wynee Sade, Presidio Investors Operating Partner Wynee’s expertise in driving growth, building brands, and leading high-performing teams has shaped organizations from early-stage startups to established Fortune 500 companies. She has a proven track record of scaling businesses and delivering impactful solutions. Wynee is also the founder of Yu Ming Charter School, California’s first public K-8 Mandarin immersion school, which has earned numerous accolades, including National Blue Ribbon recognition. Wynee holds an MBA from H
Join the 2025 Global Challenger Innovation Contest: Driving Inclusion Through Innovation28.3.2025 17:12:00 EET | Press release
The 10x1000 Tech for Inclusion community and next-generation corporate venture partner xcube.co launched the Global Challenger Innovation Contest 2025 at the JUMPSTARTER 2025 event in Hong Kong SAR, China, building on the success of the 2024 competition. Now in its second year, the contest continues to empower visionaries to create tech-driven solutions that promote inclusion and drive social impact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250328955793/en/ 10x1000 Tech for Inclusion and xcube.co jointly launched the Global Challenger Innovation Contest in Hong Kong SAR, China, at the JUMPSTARTER 2025 event. The Global Challenger Innovation Contest was inaugurated in 2024 as a flagship project of 10x1000 Tech for Inclusion, a global initiative supported by the International Finance Corporation (IFC) and Ant International, to empower emerging tech leaders to create innovative solutions for financial inclusion and social
Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category28.3.2025 15:22:00 EET | Press release
Altasciences, a nine-time CRO Leadership Award winner, is proud to announce they have been awarded a 2025 CDMO Leadership Award in the Small Molecule Dosage Form–North America category. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327305519/en/ Altasciences receives a 2025 CDMO Leadership Award in the Small Molecule Dosage Form (North America) category. Altasciences’ CDMO site supports drug development with formulation, manufacturing, and analytical testing—from discovery to commercialization. Their FDA-inspected facility features Grade C cleanrooms, R&D and analytical labs, ICH stability chambers, and a cGMP warehouse. "This recognition reflects our CDMO team’s unwavering dedication and expertise, as well as our unrelenting commitment to advancing drug development in collaboration with leading pharmaceutical and biotech innovators,” says Marie-Hélène Raigneau, Co-Chief Operating Officer at Altasciences. “We are gratefu
SES and SpeQtral Sign MoU to Advance Global Quantum-Secure Communications28.3.2025 14:49:00 EET | Press release
SES and SpeQtral signed a Memorandum of Understanding (MoU) to develop an interoperable Optical Ground Station (OGS) to establish long-distance satellite-based Quantum Key Distribution (QKD) between Asia and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250328851677/en/ SES's CEO Adel Al-Saleh and SpeQtral's CEO Chune Yang Lum sign a Memorandum of Understanding to develop an interoperable Optical Ground Station to establish long-distance satellite-based Quantum Key Distribution between Asia and Europe. Under the agreement, the development of an interoperable OGS will enable SES and SpeQtral to connect both companies’ current and future QKD satellite missions, resulting in easier access to, and diversity in the supply of long-distance QKD to end users in Asia, Europe and other future compatible ground stations worldwide. The integration of this proposed OGS with Singapore’s fibre-QKD network will help future customer
SBC Medical Group Holdings Inc. Announces Fourth Quarter and Full Year 2024 Financial Results28.3.2025 13:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical” or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for -the three months ended December 31, 2024 and full year 2024. Fourth Quarter 2024 Highlights Total revenues were $44 million, representing a 29% year-over-year decrease. Gross profit was $34 million, representing a 22% year-over-year decrease. Income from operations was $5 million, representing an 80% year-over-year decrease. EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $21 million, representing a 22% year-over-year decrease. EBITDA margin1was 47% for the fourth quarter of 2024, compared to 43% for the fourth quarter of 2023. Net income attributable to SBC Medical Group was $7 million, representing a 54% year-over-year decrease. Earnings per share, which is defined as net inc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom